Join Growin Stock Community!

和康生1783.TW Overview

TW StockBiotech. & Medical
(No presentation for 1783)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

和康生（1783）Overall Performance

和康生（1783）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

和康生（1783） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

和康生（1783）Key Information

和康生（1783）Profile

Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and skincare products in Taiwan and internationally. The company offers Formagraft, a bone graft substitute; Formasetin, a bone void filler; and intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names for use in orthopedic area. It also provides Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental grafts for use in orthopedic and dental areas. In addition, the company offers FormaAid, a collagen membrane; and E-TECH DENTISTAR II sterilizer and disinfectant for use in dental area, as well as HealiAid, a collagen wound dressing product for use in dental and wound dressing area. Further, it provides ophthalmic viscoelastic device under the ViscAid, PreviscAid, and BiVisc names; and Formaderm, a dermal filler injection for use in plastic surgery. Additionally, the company offers skincare products, including face, neck, body, limbs, and other masks; and make up remover, cleansing, exfoliating, toner, essence, men's care, sunscreen, body care, hand/foot care, and special care products. Maxigen Biotech Inc. was founded in 1998 and is based in Taoyuan City, Taiwan.

和康生（1783）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.61
PE Ratio (TTM)
16.74
Forward PE
38.24
PS Ratio (TTM)
4.95
PB Ratio
2.66
Price-to-FCF
114.38
METRIC
VALUE
vs. INDUSTRY
Gross Margin
69.33%
Net Margin
29.54%
Revenue Growth (YoY)
27.05%
Profit Growth (YoY)
26.34%
3-Year Revenue Growth
7.29%
3-Year Profit Growth
7.82%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.61
PE Ratio (TTM)
16.74
Forward PE
38.24
PS Ratio (TTM)
4.95
PB Ratio
2.66
Price-to-FCF
114.38
Gross Margin
69.33%
Net Margin
29.54%
Revenue Growth (YoY)
27.05%
Profit Growth (YoY)
26.34%
3-Year Revenue Growth
7.29%
3-Year Profit Growth
7.82%
default symbol

1783

和康生

43.70D

-0.80%

(-0.01)

  • When is 1783's latest earnings report released?

    The most recent financial report for 和康生 (1783) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1783's short-term business performance and financial health. For the latest updates on 1783's earnings releases, visit this page regularly.

  • Where does 1783 fall in the P/E River chart?

    According to historical valuation range analysis, 和康生 (1783)'s current price-to-earnings (P/E) ratio is 15.09, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 1783?

    According to the latest financial report, 和康生 (1783) reported an Operating Profit of 53.14M with an Operating Margin of 26.46% this period, representing a growth of 6.39% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 1783's revenue growth?

    In the latest financial report, 和康生 (1783) announced revenue of 200.86M, with a Year-Over-Year growth rate of 15.47%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 1783 have?

    At the end of the period, 和康生 (1783) held Total Cash and Cash Equivalents of 731.12M, accounting for 0.43 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 1783 go with three margins increasing?

    In the latest report, 和康生 (1783) achieved the “three margins increasing” benchmark, with a gross margin of 67.23%%, operating margin of 26.46%%, and net margin of 37.61%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1783's profit trajectory and future growth potential.

  • Is 1783's EPS continuing to grow?

    According to the past four quarterly reports, 和康生 (1783)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.84. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 1783?

    和康生 (1783)'s Free Cash Flow (FCF) for the period is -1.95M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 47.87% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.